Use of H19 regulatory sequences for targeted gene therapy in cancer

We present a tumor gene therapy approach based on the use of regulatory sequences of the H19 gene that are differentially expressed between normal and cancer cells. We constructed expression vectors carrying the gene for the A fragment of diphtheria toxin (DT‐A) or herpes simplex virus thymidine kinase (HSV‐tk), under the control of a 814 bp 5′‐flanking region of the H19 gene. The cell killing activity of these constructs was in accordance with the relative activity of the H19 regulatory sequences in the transfected cells. We evaluated the therapeutic potential of the gene expression constructs driven by H19 regulatory sequences in an animal model of bladder cancer induced by subcutaneous injection of syngeneic bladder tumor cell lines. Intratumoral injection of these constructs caused a significant suppression of subcutaneous tumor growth, with no obvious toxicity toward the host. © 2002 Wiley‐Liss, Inc.

[1]  R. Palmiter,et al.  Cell lineage ablation in transgenic mice by cell-specific expression of a toxin gene , 1987, Cell.

[2]  M. Hashida,et al.  Gene expression and antitumor effects following direct interferon (IFN)-γ gene transfer with naked plasmid DNA and DC-chol liposome complexes in mice , 1999, Gene Therapy.

[3]  Michael Weber,et al.  H19 gene expression is up-regulated exclusively by stabilization of the RNA during muscle cell differentiation , 2000, Oncogene.

[4]  A. Hochberg,et al.  The expression of the H19 gene and its function in human bladder carcinoma cell lines , 1999, FEBS letters.

[5]  H. Yamasaki,et al.  Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. , 2000, Cancer research.

[6]  R. Vile,et al.  In vitro and in vivo targeting of gene expression to melanoma cells. , 1993, Cancer research.

[7]  V. Erdmann,et al.  The product of the imprinted H19 gene is an oncofetal RNA. , 1997, Molecular pathology : MP.

[8]  A. Hochberg,et al.  The effect of retinoic acid on the activation of the human H19 promoter by a 3′ downstream region , 1998, FEBS letters.

[9]  G. A. Hofmann,et al.  Highly efficient electro-gene therapy of solid tumor by using an expression plasmid for the herpes simplex virus thymidine kinase gene. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[10]  I. Maxwell,et al.  Regulated expression of a diphtheria toxin A-chain gene transfected into human cells: possible strategy for inducing cancer cell suicide. , 1986, Cancer research.

[11]  M. Ishiura,et al.  Complete nucleotide sequence and characterization of the 5'-flanking region of mammalian elongation factor 2 gene. , 1988, The Journal of biological chemistry.

[12]  A. Hochberg,et al.  The imprinted H19 gene is a marker of early recurrence in human bladder carcinoma , 2000, Molecular pathology : MP.

[13]  A. Hochberg,et al.  Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone. , 1999, Cancer research.

[14]  A. Hochberg,et al.  The dynamics of the imprinted H19 gene expression in the mouse model of bladder carcinoma induced by N-butyl-N-(4-hydroxybutyl)nitrosamine. , 1998, Carcinogenesis.

[15]  G. Nabel,et al.  Immunotherapy of malignancy by in vivo gene transfer into tumors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[16]  P. Briand,et al.  The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. , 1975, Cancer research.

[17]  A. Hochberg,et al.  Developmentally imprinted genes as markers for bladder tumor progression. , 1996, The Journal of urology.

[18]  A. Hochberg,et al.  Imprinted H19 oncofetal RNA is a candidate tumour marker for hepatocellular carcinoma. , 1998, Molecular pathology : MP.

[19]  Morris Laster,et al.  Characterization of human and mouse H19 regulatory sequences , 2000, Molecular Biology Reports.

[20]  D. Liggitt,et al.  Cationic Liposome-mediated Intravenous Gene Delivery (*) , 1995, The Journal of Biological Chemistry.